Screener / SEC EDGAR /CIK 0001192448 /10-K filed Feb 23, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

GLAUKOS Corp GKOS

Compare with peers Embed
FY2025 at a glance

Sales up 32.3%, free cash flow up to -$22.5M

XBRL, from each 10-K
RevenueStatements
$507.4M from $383.5M in FY2024
FY2016FY2025
Net incomeStatements
-$187.7M from -$146.4M in FY2024
FY2016FY2025
Free cash flowStatements
-$22.5M from -$67.6M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-3.28 from $-2.77 in FY2024
FY2016FY2025
Operating marginStatements
-39.3% from -31.9% in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (39)
EPS (ttm)
-2.95
Sales (ttm)
690.3M
Net income (ttm)
-169.8M
Sales growth
+32.3%
EPS growth
-
Sales Q/Q
+58.0%
Free cash flow
36.0M
Gross margin
64.8%
Oper. margin
-25.5%
Net margin
-24.6%
FCF margin
5.2%
R&D / sales
29.7%
Dividend
-
Debt/Eq
-
Curr. ratio
4.57
Cash
162.3M
Op. cash flow (ttm)
47.7M
EBITDA
-161.5M
EBITDA margin
-31.8%
Quick ratio
4.07
Interest cover
-43.06
FCF after stock pay
-85.7M
Goodwill / assets
7.5%
Oper. margin low 5y
-40.9%
Stock pay / sales
12.5%
Shares out.
59.2M
Shares Y/Y
+8.4%
Book / share
12.12
Cash / share
2.74
Sales / share
11.66
Asset turnover
0.70
Inventory turns
1.76
Days sales out.
78
Sales 3Y CAGR
+21.5%
Sales 5Y CAGR
+17.7%
Employees
1,094
Sales / employee
631K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 507.4M +18.0% a year Net income -187.7M
FY2016 revenue 114.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001558370-19-001235 FY2016 net income 4.5M · NetIncomeLoss, 0001558370-19-001235 114.4M FY2016 FY2017 revenue 159.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001558370-20-001862 FY2017 net income -92K · NetIncomeLoss, 0001558370-20-001862 159.3M FY2017 FY2018 revenue 181.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001558370-21-002061 FY2018 net income -13.0M · NetIncomeLoss, 0001558370-21-002061 181.3M FY2018 FY2019 revenue 237.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001558370-22-002371 FY2019 net income 15.4M · NetIncomeLoss, 0001558370-22-002371 237.0M FY2019 FY2020 revenue 225.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001558370-23-002070 FY2020 net income -120.3M · NetIncomeLoss, 0001558370-23-002070 225.0M FY2020 FY2021 revenue 294.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001558370-24-001630 FY2021 net income -49.6M · NetIncomeLoss, 0001558370-24-001630 294.0M FY2021 FY2022 revenue 282.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001558370-25-001402 FY2022 net income -99.2M · NetIncomeLoss, 0001558370-25-001402 282.9M FY2022 FY2023 revenue 314.7M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-061944 FY2023 net income -134.7M · NetIncomeLoss, 0001193125-26-061944 314.7M FY2023 FY2024 revenue 383.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-061944 FY2024 net income -146.4M · NetIncomeLoss, 0001193125-26-061944 383.5M FY2024 FY2025 revenue 507.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-061944 FY2025 net income -187.7M · NetIncomeLoss, 0001193125-26-061944 507.4M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +7.7% a year FY2015 $5.45 to FY2025 $11.47, 10 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$3.28$11.47-$0.39
Dec 31, 2024 -$2.77$14.54-$1.28
Dec 31, 2023 -$2.78$9.53-$1.61
Dec 31, 2022 -$2.09$11.17-$1.34
Dec 31, 2021 -$1.07$12.65-$0.50
Dec 31, 2020 -$2.70$15.00-$0.67
Dec 31, 2019 $0.37$16.36-$0.12
Dec 31, 2018 -$0.37$4.92$0.24
Dec 31, 2017 $0.00$4.02$0.58
Dec 31, 2016 $0.12$3.22$0.17
Dec 31, 2015 -$2.13$5.45-$0.18

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $475.0M
  • − All liabilities $237.3M
  • = Net current asset value $237.7M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $656.2M
  • − Goodwill $66.7M
  • − Other intangible assets $141.9M
  • = Tangible book value $447.5M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

GKOS against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+32.3%28th of 155 · median +10.5%
Net margin
-4.1%15.3%
-24.6%130th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-23.7%119th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
5.2%94th of 145 · median 10.0%
GKOS and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
GKOS GLAUKOS Corp$690.3M +32.3%64.8%-24.6%-23.7%5.2%-
RARE Ultragenyx Pharmaceutical Inc.$730.0M +20.2%--71.8%--60.5%-
TMDX TransMedics Group, Inc.$727.6M +37.1%58.6%19.9%26.2%6.1%-
TARS Tarsus Pharmaceuticals, Inc.$682.2M +147%--102.9%-4.8%0.70
MIRM Mirum Pharmaceuticals, Inc.$670.8M +54.7%--134.8%--40.8%-
UFPT UFP Technologies Inc$649.5M +19.5%28.9%11.8%15.8%-0.20
All 162 companies in the group

Where the $507.4M of revenue came from

by product, year to Dec 31, 2025

  • Glaucoma $421.1M · 83%
  • Corneal Health $86.4M · 17%

From the segment tables in the 10-K XBRL.

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity -28.6% FY2020: -18.0% net income ÷ equity
Net margin -37.0% FY2020: -53.5% profit per $ of sales: -187.7M ÷ 507.4M
Asset turnover 0.57× FY2020: 0.22× sales per $ of assets: 507.4M ÷ 893.5M
Leverage 1.36× FY2020: 1.51× assets per $ of equity: 893.5M ÷ 656.2M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -24.6% vs 6.8%
  • Gross margin down over 5 years
    59.2% → 55.7%
  • Return on equity below 15%
    -23.7%
  • A profit in 2 of 10 years
Net margin, FY2016 to FY2025: 4.0% to -37.0%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -43.1× interest expense
  • Current assets cover current liabilities
    Current ratio 4.57

Cash and shareholders

  • Free cash flow positive in 3 of 10 years
    −$22.5M last year
  • Share count up over 5 years
    +28.5%
Free cash flow, FY2016 to FY2025: 6.0M to -22.5M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

GKOS's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue507.4M
FY2016: 114.4MFY2017: 159.3MFY2018: 181.3MFY2019: 237.0MFY2020: 225.0MFY2021: 294.0MFY2022: 282.9MFY2023: 314.7MFY2024: 383.5MFY2025: 507.4M FY2017FY2019FY2021FY2023FY2025
Net income-187.7M
FY2016: 4.5MFY2017: -92KFY2018: -13.0MFY2019: 15.4MFY2020: -120.3MFY2021: -49.6MFY2022: -99.2MFY2023: -134.7MFY2024: -146.4MFY2025: -187.7M FY2017FY2019FY2021FY2023FY2025
Free cash flow-22.5M
FY2016: 6.0MFY2017: 19.8MFY2018: 8.5MFY2019: -5.1MFY2020: -29.9MFY2021: -23.1MFY2022: -63.3MFY2023: -78.0MFY2024: -67.6MFY2025: -22.5M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay-85.7M
FY2016: -2.8MFY2017: 2.2MFY2018: -17.2MFY2019: -41.5MFY2020: -76.4MFY2021: -53.2MFY2022: -101.9MFY2023: -121.5MFY2024: -117.8MFY2025: -85.7M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-3.28
FY2016: 0.12FY2017: 0.00FY2018: -0.37FY2019: 0.37FY2020: -2.70FY2021: -1.07FY2022: -2.09FY2023: -2.78FY2024: -2.77FY2025: -3.28 FY2017FY2019FY2021FY2023FY2025
Diluted shares57.2M
FY2016: 36.5MFY2017: 34.4MFY2018: 35.3MFY2019: 41.1MFY2020: 44.5MFY2021: 46.4MFY2022: 47.4MFY2023: 48.4MFY2024: 52.8MFY2025: 57.2M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Glaucoma 421.1M83.0% +38.8%
Corneal Health 86.4M17.0% +7.7%

10-K 0001193125-26-061944, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
United States 375.0M73.9% +38.9%
International 132.4M26.1% +16.8%

10-K 0001193125-26-061944, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue114.4M159.3M181.3M237.0M225.0M294.0M282.9M314.7M383.5M507.4M
Cost of revenue16.2M21.1M25.1M38.6M91.7M66.6M69.0M75.6M94.0M111.8M
Gross profit98.2M138.2M156.2M198.4M133.2M227.4M213.9M239.1M289.5M282.8M
R&D29.2M38.9M49.7M68.3M85.4M101.0M123.3M138.8M136.4M150.6M
SG&A64.8M96.3M119.5M176.6M171.4M179.3M192.9M224.1M261.2M331.7M
Operating income4.2M-2.3M-13.0M-50.3M-123.6M-32.9M-82.3M-128.7M-122.4M-199.6M
Interest expense285K--2.6M14.1M13.4M13.7M13.6M10.0M4.6M
Pretax income4.6M1K-12.4M-50.0M-132.3M-49.3M-98.4M-133.7M-145.6M-193.0M
Income tax43K93K583K-65.5M-12.0M326K766K934K771K-5.4M
Net income4.5M-92K-13.0M15.4M-120.3M-49.6M-99.2M-134.7M-146.4M-187.7M
EPS (diluted)0.120.00-0.370.37-2.70-1.07-2.09-2.78-2.77-3.28
Diluted shares36.5M34.4M35.3M41.1M44.5M46.4M47.4M48.4M52.8M57.2M
Depreciation & amortization4.7M5.5M6.3M6.3M29.4M29.7M31.6M33.7M35.6M38.1M
EBITDA9.0M3.2M-6.7M-44.0M-94.2M-3.2M-50.7M-95.0M-86.7M-161.5M
Gross margin85.9%86.8%86.2%83.7%59.2%77.3%75.6%76.0%75.5%55.7%
Operating margin3.7%-1.4%-7.2%-21.2%-54.9%-11.2%-29.1%-40.9%-31.9%-39.3%
Net margin4.0%-0.1%-7.1%6.5%-53.5%-16.9%-35.1%-42.8%-38.2%-37.0%
Revenue growth+59.5%+39.2%+13.8%+30.7%-5.1%+30.7%-3.8%+11.3%+21.9%+32.3%
EPS growth--100%--to a loss-----

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow12.3M26.1M18.9M-369K-23.0M24.7M-33.1M-57.8M-61.3M-14.8M
Capital spending6.3M6.3M10.3M4.7M6.9M47.8M30.3M20.2M6.3M7.7M
Free cash flow6.0M19.8M8.5M-5.1M-29.9M-23.1M-63.3M-78.0M-67.6M-22.5M
Stock-based pay (added back)8.8M17.6M25.7M36.4M46.5M30.1M38.6M43.5M50.2M63.2M
Free cash flow after stock pay-2.8M2.2M-17.2M-41.5M-76.4M-53.2M-101.9M-121.5M-117.8M-85.7M
Acquisitions---------12.4M
Debt raised----287.5M-----
Investing cash flow-26.1M-12.4M-26.4M43.4M-205.1M-58.2M44.8M14.1M47.8M-77.6M
Financing cash flow-1.6M4.7M21.6M-9.6M262.5M39.3M6.3M15.0M91.5M11.9M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)8.8M17.6M25.7M36.4M46.5M30.1M38.6M43.5M50.2M63.2M
Stock-based pay / revenue7.7%11.0%14.2%15.4%20.7%10.3%13.6%13.8%13.1%12.5%
Operating lease cash paid---2.1M2.9M3.8M2.9M3.2M4.1M4.3M
Finance lease principal paid-----659K527K711K877K1.1M
Right-of-use assets---15.7M20.0M28.1M25.8M27.1M30.3M31.5M
Operating lease liabilities---16.6M21.9M30.7M29.3M31.7M35.3M37.1M
Finance lease liabilities---58.4M60.7M72.7M72.2M71.5M70.6M69.5M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GKOS/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.